Is contrast enhancement needed for diagnostic prostate MRI? - Wikidata - awgldk - TriplyDB

Is contrast enhancement needed for diagnostic prostate MRI?

Is contrast enhancement needed for diagnostic prostate MRI?

http://www.wikidata.org/entity/Q38671168

about

Score 3 prostate lesions: a gray zone for PI-RADS v2.Biparametric MRI of the prostate.

P2860

Q38598713-BE9178DD-FCB1-4D8B-8F3B-9D980F20CDC2 Q47159831-7583309D-E68A-4D69-B22D-9028E6F711AC

P2860

Is contrast enhancement needed for diagnostic prostate MRI?

http://www.wikidata.org/entity/Q38671168

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Is contrast enhancement needed for diagnostic prostate MRI?

@en

type

label

Is contrast enhancement needed for diagnostic prostate MRI?

@en

prefLabel

Is contrast enhancement needed for diagnostic prostate MRI?

@en

P1433

Q38671168-F14F53F9-03FD-416E-9E68-70F7CFAF3D78

P1476

Q38671168-1C4BF3F4-E6B1-4769-B242-477370581960

P2093

Q38671168-0D7964CB-73C2-4218-B803-91FE2C9E865A

Q38671168-35DCC971-0327-4800-99BC-42612284A3A3

Q38671168-43F38FFC-D886-46A7-ABBE-44C45F10D497

Q38671168-4C754D9B-BCDB-452C-9A87-CD0949F59244

Q38671168-6B35FE8D-91C8-4C83-8A38-C6EF6092BC36

Q38671168-7A3C2D44-3C32-408A-A682-5EDA8F4F7C27

Q38671168-7BA2A3DD-0389-4FE3-8E72-15020681418C

Q38671168-97777B26-2492-4E08-94B2-A1DD572929D2

Q38671168-9DED715D-EDE8-47F4-BC5D-1E87F6F9243E

Q38671168-ABD071FD-F523-49DA-ADDD-3E720E7A5A26

P2860

Q38671168-020AC6C7-5049-4885-AE0C-D1D9E5734E3C

Q38671168-03920D2B-5662-4747-9F36-8640B8B00EC2

Q38671168-07B75CDA-3C90-4FB3-9EE2-0E3D829AD0EF

Q38671168-08255DF2-3E92-4E3E-8632-0418C91A2CB2

Q38671168-0B9524D7-A09C-4711-8F60-AE7B8DAFFF9B

Q38671168-0F23AF5C-C184-4746-91B9-D9E146710999

Q38671168-0F4AC715-B48F-4204-B9FF-4FA601AE5EF5

Q38671168-10707783-8B31-4FBD-9B21-8BB905D0906C

Q38671168-19EE31B4-6F3D-4BBB-B4F2-8C8FD074AA5D

Q38671168-245418C4-E471-4D20-9B84-937666D5290F

P304

Q38671168-4E035672-8114-44E9-8D50-68A1D6F1F8B6

P31

Q38671168-C03A942C-E277-414E-8870-8F22CEADD638

P356

Q38671168-E8B28974-3E4B-4114-B349-3B5293E78DC1

P433

Q38671168-348243F7-7178-4D5F-A284-EDCF63F02425

P478

Q38671168-F6BF5907-BFF9-41A8-94F1-1B09054BBA86

P50

Q38671168-ED964644-6EE6-4B7C-8A3F-6959DB4B2A28

P577

Q38671168-90AA8337-4068-48A9-AFEB-03F2664BB222

P698

Q38671168-1D5EFFAB-F21C-4F04-A59B-77CEE248F3B6

P932

Q38671168-E34C898B-CA8B-4434-B910-125F090C2BE9

P356

P1433

Translational andrology and urology

P1476

Is contrast enhancement needed for diagnostic prostate MRI?

@en

P2093

Agostino Orlandi

http://www.w3.org/2001/XMLSchema#string

Alfredo D'Andrea

http://www.w3.org/2001/XMLSchema#string

Annalisa Simeone

http://www.w3.org/2001/XMLSchema#string

Corrado Maria Malaspina

http://www.w3.org/2001/XMLSchema#string

Diego Palladino

http://www.w3.org/2001/XMLSchema#string

Emanuele Orlandi

http://www.w3.org/2001/XMLSchema#string

Giampaolo Bianchi

http://www.w3.org/2001/XMLSchema#string

Giorgio Galassi

http://www.w3.org/2001/XMLSchema#string

Maria Cristina Aisa

http://www.w3.org/2001/XMLSchema#string

Michele Amenta

http://www.w3.org/2001/XMLSchema#string

P2860

ESUR prostate MR guidelines 2012

Evaluation of the PI-RADS scoring system for classifying mpMRI findings in men with suspicion of prostate cancer.

Use of the Prostate Imaging Reporting and Data System (PI-RADS) for Prostate Cancer Detection with Multiparametric Magnetic Resonance Imaging: A Diagnostic Meta-analysis.

Updated prostate imaging reporting and data system (PIRADS v2) recommendations for the detection of clinically significant prostate cancer using multiparametric MRI: critical evaluation using whole-mount pathology as standard of reference

Prostate Imaging Reporting and Data System (PI-RADS), Version 2: A Critical Look.

Standardizing Biparametric MRI to Simplify and Improve Prostate Imaging Reporting and Data System, Version 2, in Prostate Cancer Management.

Lesion volume predicts prostate cancer risk and aggressiveness: validation of its value alone and matched with prostate imaging reporting and data system score.

The presence of the gadolinium-based contrast agent depositions in the brain and symptoms of gadolinium neurotoxicity - A systematic review.

Validation of the European Society of Urogenital Radiology scoring system for prostate cancer diagnosis on multiparametric magnetic resonance imaging in a cohort of repeat biopsy patients.

Is apparent diffusion coefficient associated with clinical risk scores for prostate cancers that are visible on 3-T MR images?

P304

499-509

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.21037/TAU.2017.05.31

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

Eugenio Martorana

P577

2017-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28725592

http://www.w3.org/2001/XMLSchema#string

P932

5503975

http://www.w3.org/2001/XMLSchema#string